Nadine Wong, editor of the BioTech Stock Report newsletter, sees possible buyouts in the drug discovery business. Learn why and read about Pfizer (NYSE: PFE) as well as GTx (Nasdaq: GTXI). Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84
Highlights from the November 1 Featured Expert column by Nadine Wong include:
The Biotech Indices have shot up about 10% over the last six weeks, which is a clear indicator that investors are anxiously anticipating something big. One potential outcome is a round of buyouts in the drug discovery business, with Pfizer (NYSE: PFE) as the hunter looking for its prey; an attractive biotech with promising technology and near ripe pipeline. Depending on the target(s), a host of Big Pharma companies are expected to weigh in on the bidding. So, let the games begin.
Then, there is GTx (Nasdaq: GTXI), which has fallen of late, despite the potential to file an NDA in the U.S. for its lead compound, Acapodene.
Acapodene is a selective estrogen receptor modulator (SERM) that is the subject of two pivotal Phase III trials being conducted under SPAs, for the amelioration of side effects of androgen deprivation therapy (ADT) in men with prostate cancer and for the prevention of prostate cancer. The standard-of-care for men with locally advanced or metastatic prostate cancer or more recently high-risk patients is ADT, which carries with it severe side-effects such as bone loss. At present there are over 1 million men on ADT in the U.S. Positive interim analyses provide confidence that top-level results from the pivotal Phase III trial evaluating 80 mg Acapodene for the treatment of side-effects associated with ADT will be positive. The results are expected in the first quarter of 2008.
The odds of trial success and ultimate approval in this $600 million indication are high. The lipid lowering benefit demonstrated by Acapodene is clinically meaningful and a significant differentiator from competitors. Further confidence in the trial outcome is gained from the broad safety database that has been compiled for toremifene, the active ingredient in Acapodene, is backed by 350,000+ patient years of safety data and is already approved for the treatment of metastatic breast cancer.
An interim analysis of the Phase III trial evaluating 20 mg Acapodene for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia is expected to occur in the first quarter of 2008, assuming 281 clinical events have occurred. Overall, we are optimistic about Acapodene’s ability to prevent prostate cancer given the intriguing Phase II results demonstrating that participants treated for a full year with 20 mg toremifene had a 48% reduction in the incidence of prostate cancer versus placebo. Positive prostate prevention data could mean blockbuster status for Acapodene.
Read Nadine Wong’s complete commentary by clicking: http://at.zacks.com/?id=85
About Zacks Featured Experts
Successful investing requires professional advice from knowledgeable experts who can help investors achieve their financial goals in good markets and improve their portfolios, especially in bad ones. That is why Zacks Investment Research has assembled the best investment experts in the business to offer their powerful advisory newsletters on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc.
Additional recommendations from Zacks.com Featured Experts are highlighted in the free investment newsletter, Profit from the Pros. Certain issue highlights several Featured Experts in this free e-mail newsletter. Register for a free subscription to “Profit from the Pros” at: http://at.zacks.com/?id=86
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=87.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contacts:
Alex Kolb
Phone: 312-265-9149
Email: pr@zacks.com
Visit:
www.Zacks.com
